Compare AbCellera Biologics Inc (ABCL) vs Expensify Inc (EXFY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs Expensify Inc — how do they compare? AbCellera Biologics Inc trades at $10.11 (market cap $2.99B), while Expensify Inc trades at $2.24 (market cap $209.73M). The key difference: AbCellera Biologics Inc is far larger — about 14.3× Expensify Inc's market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Expensify Inc nearer its low. Which is the better fit depends on your goals.
| ABCL | EXFY | |
|---|---|---|
Market Cap | $2.99B | $209.73M |
Sector | Health | Technology |
52-Week High | $9.76 | $2.69 |
52-Week Low | $2.78 | $0.75 |
Enterprise Value | $2.58B | $149.35M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABCL's stock rose 7.07% to $10.00, buoyed by positive Phase 2 trial results for its menopause drug ABCL635, which demonstrated an 83% reduction in hot flashes (Business Wire, August 10, 2026). Despite negative profitability margins and cash burn, technical indicators show a bullish trend with strong moving average support. The company maintains a solid balance sheet with $625.61 million in cash and low debt, though revenue declined from $485 million in 2022 to $75 million in 2025.
The outlook hinges on clinical success and monetization of ABCL635, with a consensus price target of $15.50 implying 55% upside. Key risks include prolonged cash burn, drug development setbacks, and competitive pressures. Analyst sentiment is overwhelmingly bullish (91.67% buy ratings), but investors must weigh high valuation multiples against unproven commercial traction.
EXFY trades at $2.27, down 8.1% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $33.9 million with improved profitability and cash flow, beating EPS expectations. Recent news highlights expansion into Europe and AI product enhancements. Valuation ratios show a high P/E of 258.82 but reasonable P/S of 1.56, while profitability metrics remain negative.
Outlook is cautiously optimistic due to earnings beats and strategic growth initiatives, but risks include persistent net losses and competitive pressures. Analyst sentiment is mixed with a Buy consensus but requires monitoring of margin improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Expensify Inc
Expensify Inc is a cloud-based expense management software platform that helps the smallest to the largest businesses simplify the way they manage money. More than 10 million people use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay, and travel booking in one app.
Read more on EXFY →
